Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
Provided By GlobeNewswire
Last update: Mar 26, 2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025
Read more at globenewswire.com33.06
-2.04 (-5.81%)
Find more stocks in the Stock Screener
MTSR Latest News and Analysis
3 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.Let's have a look at the gap up and gap down stocks in today's session.
3 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
